請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44885
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲 | |
dc.contributor.author | Yen-Ju Chen | en |
dc.contributor.author | 陳彥汝 | zh_TW |
dc.date.accessioned | 2021-06-15T03:57:20Z | - |
dc.date.available | 2015-09-13 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-06-15 | |
dc.identifier.citation | 1. WHO. Promoting safety of medicines for children. 2007:1-62.
2. Reflection paper: Formulatios of choice for the paediatric population. London: Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMEA); 2006:1-45. 3. Barbosa Santos D, Clavenna A, Bonati M, Lutescia Luna Coelho H. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. European Journal Of Clinical Pharmacology. 2008;64:1111-1118. 4. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. British Medical Journal. 2000;320:79-82. 5. Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. British Journal of Clinical Pharmacology. 2002;54:665-570. 6. Pandolfini C, Bonati M. A literature review on off-label drug use in children. European Journal of Pediatrics. 2005;164:552-558. 7. Schaefer MK, Shehab N, Cohen AL, Budnitz DS. Adverse events from cough and cold medications in children. Pediatrics. 2008;121:783-787. 8. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. Journal Of the American Medical Association. 1995;274:29-34. 9. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. Journal Of the American Medical Association. 1997;277:307-311. 10. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. Journal Of the American Medical Association. 2001;285:2114-2120. 11. Breitkreutz J. European perspectives on pediatric formulations. Clinical Therapeutics. 2008;30:2146-2154. 12. 陳佳其. 台灣兒童族群門診中口服兒童製劑使用情形. [碩士論文] 指導教授:林慧玲副教授. 台北市: 臨床藥學研究所, 國立台灣大學; 2009. 13. 李宛樺. 兒童抗組織胺處方形態研究與用藥安全分析. [碩士論文] 指導教授:何蕴芳助理教授.台北市: 臨床藥學研究所, 國立台灣大學; 2009. 14. Milchev AI, Milchev AA. Wetting behavior of nanodroplets: The limits of Young's rule validity. Europhys Lett. 2001;56:695-701. 15. Piepsz A, Hahn K, Roca I, et al. A radiopharmaceuticals schedule for imaging in paediatrics. European Journal of Nuclear Medicine and Molecular Imaging. 1990;17:127-129. 16. ICH. Guidance for Industry E11 Clinical Investigation of Medicinal Products in the Pediatric Population. In: Services DoHaH, FDA, eds2000. 17. Taketomo C, Hooding H, Kraus M. Pediatric Dosage Handbook: Lexi-Comp's; 2008. 18. Kraus DM, Pham JT. Neonate Therapy. In: Koda-Kimble MA, Young LY, Alldredge BK, et al., eds. Applied therapeutics: the clinical use of drugs. 9 ed: Lippincott Williams & Wilkins; 2009:94-91~94-55. 19. Nahata MC, Taketomo C. Pediatrics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill; 2008:47-56. 20. Luedtke S. Pediatric and Neonatal Therapy. In: Helms RA, Quan DJ, Herfindal ET, Gourley DR, eds. Textbook of Therapeutics. Drug and Disease Management. 8th ed: Lippincott Williams &Wilkins; 2006:325-339. 21. Holtkamp K, Peters-Wallraf B, Wuller S, Pfaaffle R, Herpertz-Dahlmann B. Methylphenidate-related growth impairment. J Child Adol Psychop. 2002;12:55-61. 22. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clinical Pharmacokinetics. 2002;41:959-998. 23. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clinical Pharmacokinetics. 2002;41:1077-1094. 24. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. New England Journal of Medicine. 2003;349:1157-1167. 25. Menon PA, Thach BT, Smith CH, et al. Benzyl alcohol toxicity in a neonatal intensive care unit. Incidence, symptomatology, and mortality. American Journal of Perinatology. 1984;1:288-292. 26. Strickley RG, Iwata Q, Wu S, Dahl TC. Pediatric drugs-a review of commercially available oral formulations. Journal Of Pharmaceutical Sciences. 2008;97:1731-1774. 27. Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clinical Therapeutics. 2008;30:2120-2132. 28. Ceci A, Felisi M, Baiardi P, et al. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. European Journal Of Clinical Pharmacology. 2006;62:947-952. 29. Ceci A, Felisi M, Catapano M, et al. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. European Journal Of Clinical Pharmacology. 2002;58:495-500. 30. Rossignoli A, Clavenna A, Bonati M. Antibiotic prescription and prevalence rate in the outpatient paediatric population: analysis of surveys published during 2000-2005. European Journal Of Clinical Pharmacology. 2007;63:1099-1106. 31. Clavenna A, Rossi E, Derosa M, Bonati M. Use of psychotropic medications in Italian children and adolescents. European Journal of Pediatrics. 2007;166:339-347. 32. Bonati M. Epidemiologic evaluation of drug use in children. The Journal of Clinical Pharmacology. 1994;34:300. 33. Sturkenboom MCJM, Verhamme KMC, Nicolosi A, et al. Drug use in children: cohort study in three European countries. British Medical Journal. 2008;337:a2245. 34. Clavenna A, Bonati M. Drug prescriptions to outpatient children: a review of the literature. European Journal Of Clinical Pharmacology. 2009;65:749-755. 35. Dimri S, Tiwari P, Basu S, Parmar V. Drug use pattern in children at a teaching hospital. Indian Pediatrics. 2009;46:165-167. 36. National List of Essential Medicines. In: India Go, ed. New Delhi: Ministry of Health and Family Welfare; 2003. 37. Clavenna A, Berti A, Gualandi L, Rossi E, De Rosa M, Bonati M. Drug utilisation profile in the Italian paediatric population. European Journal of Pediatrics. 2009;168:173-180. 38. Niclasen B, Moller S, Christensen R. Drug prescription to children living in the Arctic. An investigation from Nuuk, Greenland. Arctic medical research. 1995;54:95. 39. Niclasen BV. Changes in drug prescription over a decade in an Arctic child population. Acta Paediatrica. 2006;95:1456-1460. 40. Thrane N, Sorensen HT. A one-year population-based study of drug prescriptions for Danish children. Acta Paediatrica. 1999;88:1131-1136. 41. Schirm E, van den Berg P, Gebben H, Sauer P, de Jong-van den Berg L. Drug use of children in the community assessed through pharmacy dispensing data. British Journal of Clinical Pharmacology. 2000;50:473-478. 42. Madsen H, Andersen M, Hallas J. Drug prescribing among Danish children: a population-based study. European Journal Of Clinical Pharmacology. 2001;57:159-165. 43. Hong S, Shepherd M. Outpatient prescription drug use by children enrolled in five drug benefit plans. Clinical Therapeutics. 1996;18:528-545. 44. Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clinical Therapeutics. 2008;30:2133-2145. 45. Administration. UFaD. Pediatric Drug Development. http://www.fda.gov/cder/pedlatrlcs/lndex.htm#pedexd-stats. Accessed May 7, 2010. 46. Administration. UFaD. Pediatric exciusivity labeling changes as of August 8, 2007. http://www.fda.gov/cder/pedlatrlc/labelchange.htm. Accessed May 7, 2009. 47. 中央健康保險局. 健保用藥品項查詢. http://www.nhi.gov.tw/inquire/query1.asp?menu=1&menu_id=8&WD_ID=8. Accessed Dec 4, 2009. 48. To err is human. Building a safer health system. In: Kohn LT, Corrigan JM, Donaldson MS, eds. Washington DC: Institute of Medicine, National Academy Press; 1999: http://www.nap.edu/catalog.php?record_id=9728. 49. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. New England Journal of Medicine. 1991;324:377-384. 50. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. New England Journal of Medicine. 1991;324:370-376. 51. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet. 1998;351:643-644. 52. Lesar TS, Briceland LL, Delcoure K, Parmalee JC, Masta-Gornic V, Pohl H. Medication prescribing errors in a teaching hospital. Journal Of the American Medical Association. 1990;263:2329-2334. 53. Lesar TS. Errors in the use of medication dosage equations. Arch Pediat Adol Med. 1998;152:340-344. 54. Alkema GE, Wilber KH, Simmons WJ, Enguidanos SM, Frey D. Prevalence of potential medication problems among dually eligible older adults in medicaid waiver services. Ann Pharmacother. 2007;41. 55. Long AJ, Chang P, Li YC, Chiu WT. The use of a CPOE log for the analysis of physicians' behavior when responding to drug-duplication reminders. Int J Med Inform. 2008;77. 56. Rimsza M, Newberry S. Unexpected infant deaths associated with use of cough and cold medications. Pediatrics. 2008;122:318-322. 57. DRUGDEX System. MICROMEDEXR 1.0 (Healthcare Series).2010. http://library2.mc.ntu.edu.tw/hcs/librarian. Accessed Nov 11, 2009. 58. 食品藥物管理局. 藥物食品安全週報第209期. 2009. Accessed May 28, 2010. 59. Berlin CM, McCarver-May DG. Use of codeine- and dextromethorpan-containing cough remedies in children. Pediatrics. 1997;99:918-920. 60. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Cough and cold medication use by US children, 1999-2006: results from the slone survey. Pediatrics. 2008;122:323-329. 61. 中央健康保險局. 2009全民健康保險簡介: 朱澤民; 2009:1-56. 62. 全民健康保險研究醫資料庫. http://w3.nhri.org.tw/nhird/. Accessed Apr 10, 2010. 63. 內政部統計處. 內政統計年報. http://sowf.moi.gov.tw/stat/year/list.htm. Accessed Mar 01, 2010. 64. 行政院衛生署. 行政院衛生署統計資料. http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=10902&class_no=440&level_no=2. Accessed Mar 24, 2010. 65. Free online searchable ICD-9-CM. 2009; http://icd9cm.chrisendres.com/. Accessed Apr 20, 2010. 66. 中央健康保險局. http://www.nhi.gov.tw/. Accessed Mar 4, 2010. 67. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. 2010; http://www.whocc.no/atc_ddd_index/. Accessed Mar 4, 2010. 68. 行政院衛生署. 西藥 、醫療器材、化粧品許可證查詢. http://203.65.100.151/DO8180.asp. Accessed Mar 4, 2010. 69. 內政部統計處. 內政統計通報. 2006. Accessed May 10, 2010. 70. Nunn T, Williams J. Formulation of medicines for children. British Journal of Clinical Pharmacology. 2005;59:674-676. 71. MARTINDALE - The Complete Drug Reference.2010. 72. Benitz WE, Tatro DS. The pediatric drug handbook. Chicago: Year Book Medical Publishers, Inc.; 1988. 73. 食品藥物管理局. 指示藥品審查基準. 台北市: 行政院衛生署; 2000. 74. 食品藥物管理局. 國人營養素參考攝取量. 台北市: 行政院衛生署; 2004. 75. WHO. WHO child growth standards. In: Department of Nutrition for Health and Development WHO, ed2006. 76. 李秉穎. 小孩的正常生長曲線. 1999; http://olddoc.tmu.edu.tw/pinging/health/he10.htm. Accessed Mar. 3, 2010. 77. 台灣諾和諾德. 兒童身高、體重生長曲線表. http://www.novonordisk.com.tw/documents/article_page/document/GrowthChart.asp. Accessed Feb. 20, 2010. 78. 國民健康局. 國民健康局-兒童身長曲線圖. 2009. Accessed Mar. 5, 2010. 79. Liang K-YZ, S. L. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22. 80. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44885 | - |
dc.description.abstract | 研究背景
增加適合的兒童製劑與促進兒童用藥安全為各國推動之目標,台灣兒童用之藥品不乏複方製劑,然而目前尚未了解台灣全民健保給付之複方藥品中適合兒童使用的比例,與這些複方製劑實際開方情形。 研究目的 了解台灣現有健保給付之口服複方製劑中,符合理想兒童的複方製劑及比例;利用健保資料庫,調查台灣兒童門診開立複方製劑之處方型態,及合理口服複方兒童製劑實際使用情形。 研究材料與方法 研究材料為2009年7月公布之全民健保用藥品項資料中口服複方製劑部分,與2005年至2008年全民健保資料庫基本資料檔及百萬承保抽樣歸人檔。 依複方製劑是否有兒童適應症與兒童使用劑量資訊、成分含量是否適合兒童使用、劑型是否方便兒童使用、重複藥理機轉及成分含量比例,來篩選出適合未滿12歲兒童使用之複方製劑,再依適用年齡分組為未滿6歲及6歲至未滿12歲,討論這些適合複方製劑之組成與特性。 以健保資料庫中未滿12歲兒童門診就醫資料,分析含複方製劑之處方型態,包括兒童就醫之醫療院所特約別、開立處方的地區與分局別、就醫科別分布、就醫之診斷與開方複方製劑之藥理分布;計算適合兒童使用之複方製劑開方筆數與在各醫院醫療層級、開立藥品所屬各分局別與各開方科別的開方比例;以SAS軟體進行迴歸分析,探討哪些因素可能影響複方製劑的開立,與影響合理的複方兒童製劑的開立。 研究結果 2009年7月健保給付之用藥品項中,共有1348筆複方藥品,包括219種學名核價主成分及23種劑型。其中適合兒童使用之複方製劑共有317筆(23.5%),包含無劑量資訊但經臨床判斷兒童可使用的有21筆(1.6%)、適合未滿6歲兒童使用之複方兒童製劑有205筆(15.2%)。所有適合兒童使用之複方製劑中,參考文獻資料較完整的西方典籍劑量資訊篩選出的只有130筆,佔所有複方製劑之9.6%。這些複方兒童製劑藥理分類最多的依序為腸胃道及代謝(35.5%)、感染(28.0%)與呼吸系統(20.6%);而各藥理分類中合理複方兒童製劑佔所有複方製劑的比例以感染(79.1%)最高,在全身性荷爾蒙、腫瘤及免疫調節與感覺系統類則沒有任何適合兒童使用之複方製劑。 健保資料庫未滿12歲兒童的門診就醫處方資料中,有9成的處方箋是由基層院所開立,而在所有含口服藥品處方中約有55%~60%處方含有至少一個(含)複方製劑;開方複方製劑主要藥理類別分布有7成以上是呼吸系統類;就醫診斷也是以呼吸道疾病為主。而適合兒童使用之複方製劑佔所有複方製劑開方次數比例,就醫年齡未滿6歲之兒童平均開方比例為11.2%(醫學中心、區域醫院、地區醫院、基層院所各為10.9%、13.4%、11.0%、11.1%);就醫年齡6歲至未滿12歲之兒童平均開方比例為10.3% (醫學中心、區域醫院、地區醫院、基層院所各為12.4%、12.7%、9.2%、10.2%),而最常開方之合理複方製劑藥理分類,則是腸胃道及代謝為最高(87.4%),呼吸系統只佔2.4%;各藥理分類中適合兒童使用的複方製劑開方比例,則是以其他類(100%)與腸胃道及代謝(55.4%)最高,而呼吸系統中只佔(0.3%)。 結論 本研究為台灣地區第一個針對兒童使用口服複方製劑情形與其門診開方型態的研究。台灣至2009年7月健保給付的口服藥品中,適合未滿12歲兒童使用之合理複方兒童製劑佔所有複方製劑之23.5%,但真正參考西方文獻資料完整的只佔9.6%;而在健保資料庫中兒童門診處方資料中,適合兒童使用的複方製劑開方次數只佔所有開方複方製劑之10.3%~11.2%,在基層院所中開立未滿6歲理想製劑更只有2.2%,表示兒童使用到複方製劑有相當的比例並不適當,尤其以呼吸道系統問題最多。 | zh_TW |
dc.description.abstract | Background
Improving pediatric drug safety and increasing the number of pediatric formulations are important issues all over the world. In Taiwan, there are many multiple- active ingredients medications for children. The appropriate and the utilization of these multiple-active ingredients medications in children are unknown. Objective To understand the availability and appropriateness of multiple-active ingredients medications for children as well as their prescribing pattern for pediatric outpatients in Taiwan. Materials and Methods The drug database we used was the drug formulary issued by the Bureau of National Health Insurance (NHI) in July, 2009. The outpatient prescriptions were obtained from the longitudinal database and registration datasets from the National Health Insurance Research Database between 2005 and 2008. The criteria to evaluate the appropriateness of multiple- active ingredients medications for children younger than 12 years include: indications, dosing information of active ingredients for children, unit contents, dosage form, and therapeutic duplications of the active ingredients and dosing ratio. The appropriate for children were divided into those for children younger than 6 y/o and those for children 6-12 y/o. We analyzed the outpatient prescriptions for children younger than 12 y/o which contain at least one multiple- active ingredients medications. The utilization of multiple- active ingredients medications in different clinical setting, medical divisions and diagnosis were analyzed. We used SAS (version 9.1.3 SAS Institute Inc., Cary, NC, U.S.A.) to do multiple regression to explore the influence factors. Results Of the NHI formulary, there are 1348 oral multiple- active ingredients medications were included in the study. These included 219 major active ingredients and 23 dosage forms. The percentage of multiple- active ingredients medications appropriateness for children younger than 12 y/o is 23.5% (317), including 21 (1.6%) considered suitable for children without pediatric dosage information. Among them, there were 205 (15.2%) were suitable for children younger than 6 y/o. Only 130 (9.6%) of all the multiple- active ingredients medications met all the criteria of an ideal pediatric. The most common proportion suitable for children were agents for alimentary tract and metabolism (35.5%), antiinfectives (28.0%) and respiratory system (20.6%). Systemic hormonal preparations, excl. Sex hormones and insulins, antineoplastic and immunomodulating agent, and sensory organs had no suitable multiple- active ingredients medications for children. About 90% of the prescriptions for children younger than 12 y/o were prescribed in primary care clinics, and there were 55%~60% prescriptions contained at least one multiple- active ingredients medications. The major diagnoses for children were diseases of respiratory system. The most often prescribed medications were those used for respiratory system (70%). The utilization of appropriate multiple- active ingredients medications were 11.2% in children younger than 6 y/o, and 10.3% in children between 6 and 12 y/o. Of the multiple- active ingredients prescriptions, 87.4%of drugs for alimentary tract and metabolism were preparations appropriate for children, while only 0.3% prescription of drugs for respiratory system were appropriate. Conclusions About 23.5% of multiple- active ingredients medications can be used in children younger than 12 y/o, only 9.6% are ideal pediatric dosage forms. Only 10.3%~11.2% of the multiple- active ingredients medications were preparation suitable for children. In primary care clinics, only 2.2% of the multiple- active ingredients medications prescription ideal pediatric dosage forms. Most children received multiple- active ingredients medications with inappropriate components, doses, or dosage forms, especially drugs for respiratory diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T03:57:20Z (GMT). No. of bitstreams: 1 ntu-99-R97451002-1.pdf: 8995269 bytes, checksum: 0f9dde15903e334e6456c59a4e682c03 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 誌謝 ii
中文摘要 iii Abstract vii 目錄 x 圖目錄 xii 表目錄 xiii 附錄表目錄 xiv 第1章 前言 1 第2章 文獻回顧 2 2.1 兒童製劑適當性評估 2 2.1.1 兒童族群之年齡定義 2 2.1.2 兒童的生理與藥品動態學特性 2 2.1.3 兒童製劑(pediatric formulations) 6 2.1.4 兒童門診處方型態分析 10 2.1.5 各國相關法令與政策 13 2.2 兒童藥品治療相關問題 15 2.2.1 藥品用藥疏失 15 2.2.2 重複用藥 16 2.2.3 感冒咳嗽製劑之藥品不良反應 16 2.3 兒童使用複方製劑情形 18 2.4 台灣全民健康保險與台灣兒童族群概況 18 2.4.1 台灣全民健康保險與全民健康保險資料庫 18 2.4.2 兒童族群人口統計與門診就醫背景 19 第3章 研究目的 20 第4章 研究材料及方法 21 4.1 研究材料 21 4.1.1 全民健康保險用藥品項 21 4.1.2 全民健康保險研究資料庫基本資料檔及百萬承保抽樣歸人檔 21 4.2 研究方法 23 4.2.1 篩選合理複方兒童製劑 24 4.2.2 兒童族群門診處方分析 32 4.2.3 資料整理與統計分析 35 第5章 研究結果 37 5.1 合理複方兒童製劑篩選 37 5.1.1 合理複方兒童製劑篩選結果 37 5.1.2 合理複方兒童製劑分析 41 5.2 兒童門診處方型態分析 47 5.2.1 含複方藥品之處方型態分析 49 5.2.2 合理複方兒童製劑開方情形 56 5.3 迴歸分析 65 5.3.1 口服複方製劑開立相關因子之分析 65 5.3.2 合理複方兒童製劑開立相關因子之分析 69 第6章 討論 73 6.1 合理複方兒童製劑之定義與篩選 73 6.1.1 合理複方兒童製劑之評估 73 6.1.2 合理複方兒童製劑之篩選結果 74 6.2 兒童門診處方型態分析 77 6.2.1 門診處方盛行率與開立藥品數 77 6.2.2 開方藥品藥理分類分布 78 6.2.3 合理複方兒童製劑開方情形 79 6.2.4 影響複方製劑開立與否因素之分析 80 6.2.5 影響合理複方兒童製劑開立與否因素之分析 81 6.3 研究限制 82 6.3.1 合理複方兒童製劑篩選 82 6.3.2 兒童門診處方分析 82 6.4 未來展望 84 第7章 結論 85 參考文獻 87 附錄一 指示藥品審查基準(腸胃製劑) 93 附錄二 指示藥品審查基準(綜合感冒製劑) 112 附錄三 合理複方兒童製劑篩選結果流程圖 128 | |
dc.language.iso | zh-TW | |
dc.title | 臺灣口服複方兒童製劑之合理性及門診處方型態分析 | zh_TW |
dc.title | Rationality of Commercial Oral Multiple-Active Ingredients Medications and Outpatient Prescription Patterns for Children in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李秉穎,沈麗娟,何?芳 | |
dc.subject.keyword | 兒童,複方製劑,全民健康保險,門診處方型態,台灣, | zh_TW |
dc.subject.keyword | Child,National Health Insurance,Outpatients,Prescriptions,Taiwan, | en |
dc.relation.page | 144 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-06-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 8.78 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。